Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
HIV Med ; 13(7): 436-8, 2012 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-22276852

RESUMO

OBJECTIVE: A Swiss nonoccupational post-exposure prophylaxis (NPEP) source-tracing study successfully reduced unnecessary NPEP prescriptions by recruiting and testing source partners of unknown HIV serostatus. The Victorian NPEP Service in Australia attempted to replicate this study with the addition of HIV rapid testing and a mobile service. METHODS: Patients presenting to two busy NPEP sites who reported a source partner of unknown HIV status were routinely asked if their source could be traced. If the exposed person indicated that their source partner was traceable they were asked to contact them and discuss the possibility of having an HIV test. RESULTS: No sources were enrolled and the study was terminated. CONCLUSION: We hypothesize that there are a number of differences between Australia and Switzerland that make source tracing unfeasible in Australia.


Assuntos
Fármacos Anti-HIV/provisão & distribuição , Busca de Comunicante/métodos , Prescrições de Medicamentos/estatística & dados numéricos , Soropositividade para HIV/diagnóstico , Profilaxia Pós-Exposição/provisão & distribuição , Fármacos Anti-HIV/economia , Fármacos Anti-HIV/uso terapêutico , Austrália/epidemiologia , Busca de Comunicante/economia , Análise Custo-Benefício , Estudos de Viabilidade , Feminino , Soropositividade para HIV/tratamento farmacológico , Soropositividade para HIV/economia , Soropositividade para HIV/epidemiologia , Humanos , Masculino , Seleção de Pacientes , Profilaxia Pós-Exposição/economia , Parceiros Sexuais , Suíça/epidemiologia , Vitória/epidemiologia
2.
J Clin Microbiol ; 41(1): 227-36, 2003 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-12517853

RESUMO

Genotypic antiretroviral testing is now widely used for the management of patients who are undergoing antiretroviral therapy for human immunodeficiency virus infection. The assays are complex, and there is considerable potential for variation between laboratories. Informative and ongoing quality assessment programs (QAPs) which address all aspects of testing are required. The panel distribution of clinical material is a critical component of QAPs. We report on the results and data from a recent panel. Four cryopreserved plasma samples from treated donors were distributed to nine laboratories. Three laboratories performed testing by commercial assays, and six laboratories used in-house assays, with one laboratory reporting results from two in-house assays. There was complete concordance between results for 95.9% of the nucleotide sequence and 94.5% of the amino acid sequence. Despite this overall high level of concordance, the degree of concordance at drug resistance mutation (DRM) sites when DRMs were present was considerably less (38% of DRM sites). Consequently, only 3 of the 10 methods reported 100% of DRMs as present. This elevated discrepancy rate is almost certainly a result of variability in the identification of mixtures of nucleotides (mixtures) at any site within the sequence. In addition, laboratories differed in the number of codons in the reverse transcriptase gene that were sequenced and their ability to amplify all samples. This panel distribution demonstrated a requirement for laboratory participation in ongoing QAPs and the optimization of assays with standards that contain mixtures.


Assuntos
Farmacorresistência Viral/genética , Transcriptase Reversa do HIV/genética , Fármacos Anti-HIV/uso terapêutico , Terapia Antirretroviral de Alta Atividade , Monitoramento Ambiental , Genótipo , Infecções por HIV/tratamento farmacológico , Infecções por HIV/virologia , HIV-1/efeitos dos fármacos , HIV-1/enzimologia , Humanos , Mutação , Análise de Sequência de DNA
3.
Mol Pharmacol ; 22(1): 5-7, 1982 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-6289075

RESUMO

The binding of [3H]dihydroalprenolol to adipocyte membranes may be displaced not only from beta-adrenergic receptors but also nonstereospecifically from other membrane compartments by beta-adrenergic and other adrenergic agents. The EC50 of this nonstereospecific displaceable binding is directly related to the liposolubility (n-octanol:water partition coefficient) of the displacing ligand.


Assuntos
Receptores Adrenérgicos beta/metabolismo , Receptores Adrenérgicos/metabolismo , Simpatomiméticos/metabolismo , Tecido Adiposo/metabolismo , Animais , Ligação Competitiva , Di-Hidroalprenolol , Isoproterenol/metabolismo , Ligantes , Lipídeos de Membrana , Membranas/metabolismo , Solubilidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA